UCB's Bimekizumab Beats Skyrizi in Head-to-Head PsA Trial
Event summary
- UCB's bimekizumab demonstrated statistically significant superiority over risankizumab (Skyrizi) in the BE BOLD Phase 3 trial for active psoriatic arthritis (PsA) at Week 16, as measured by the ACR50 endpoint.
- The BE BOLD trial included 553 adult participants with active PsA, some previously exposed to TNF inhibitors.
- This marks the fourth head-to-head study showing bimekizumab's superiority across psoriatic diseases.
- Bimekizumab is the first biologic therapy to demonstrate superiority over an IL-23 inhibitor in a PsA trial.
The big picture
The PsA market is a significant segment within the broader immunology space, with a growing demand for more effective therapies. UCB's demonstration of superiority over a leading competitor like AbbVie's Skyrizi positions bimekizumab as a potential blockbuster, but also intensifies competition in a crowded market. The dual IL-17A/IL-17F inhibition mechanism of bimekizumab may prove to be a key differentiator, but its long-term efficacy and safety profile will be critical for sustained success.
What we're watching
- Market Adoption
- The speed of bimekizumab adoption will depend on physician and patient perception of its superiority, particularly given the established market share of risankizumab and other IL-23 inhibitors.
- Regulatory Approval
- Full results from the BE BOLD trial will be presented at an upcoming congress, and UCB's submission to regulatory bodies will be closely scrutinized for any unexpected findings or labeling changes.
- Competitive Response
- AbbVie, the manufacturer of risankizumab, will likely respond with further clinical data or marketing initiatives to defend its market position and highlight any potential advantages of its product.
Related topics